{"classes":[{"categories":[{"measurements":[{"comment":"Value not reached","groupId":"OG000","lowerLimit":"1.4","upperLimit":"NA","value":"3.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Survival statistics will be estimated using the Kaplan-Meier method. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. 95% confidence intervals will be provided for estimates of interest where possible.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.\n\nziv-aflibercept: Given IV","id":"OG000","title":"Treatment (Ziv-aflibercept)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Survival (Carcinosarcoma Group)","type":"SECONDARY","unitOfMeasure":"months"}